Loading
NASDAQHealthcareBiotechnology
Latest quote
$5.84
+$0.09 · +1.57%
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.
Previous close
$5.84
+$0.09 · +1.57%
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
43
Fair Value
Sentiment
53
Mixed
Risk
69
High Risk
Momentum
39
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.
Day range
Current $5.84
52-week range
Current $5.84
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | 3.31K USD | 4.13K USD | 11.76K USD | 13.07K USD |
| Gross profit | — | −3.31K USD | −4.13K USD | −11.76K USD | −13.07K USD |
| Research and development | 9.77M USD | 9.29M USD | 14.1M USD | 9.3M USD | 9.81M USD |
| Selling, general, and administrative | 6.21M USD | 5.61M USD | 4.77M USD | 5.62M USD | 4.67M USD |
| Operating expenses | 15.99M USD | 14.9M USD | 18.86M USD | 14.92M USD | 14.47M USD |
| Interest income | 153.79K USD | 60.26K USD | 27.69K USD | — | 9.29 USD |
| Interest expense | 15.23K USD | 16.12K USD | 13.81K USD | 7.03K USD | 9.29K USD |
| Depreciation and amortization | 3.92K USD | 3.31K USD | 4.13K USD | 11.76K USD | 13.07K USD |
| Operating income | −15.99M USD | −14.9M USD | −18.87M USD | −14.93M USD | −14.49M USD |
| Net income | −15.85M USD | −14.86M USD | −18.85M USD | −15.27M USD | −14.5M USD |
Company facts updated Sep 12, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$0.50
91.44% downsideLimited analyst sample: 4 ratings. Interpret the distribution with caution.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jul 22, 2025 | 1:12 | — | — |
Stock split | Feb 21, 2025 | 1:50 | — | — |
Stock split | Jun 5, 2024 | 1:50 | — | — |
Stock split | Nov 29, 2022 | 1:30 | — | — |
Effective Jul 22, 2025
1:12
Effective Feb 21, 2025
1:50
Effective Jun 5, 2024
1:50
Effective Nov 29, 2022
1:30
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
